Results 51 to 60 of about 6,998 (166)

Complement Factor H‐Based Therapeutics: A Comprehensive Overview

open access: yesEuropean Journal of Immunology, Volume 56, Issue 7, July 2026.
Complement factor H is a central regulator of the complement system and thus a target for therapeutic intervention. In this review, we provide an overview of past and current factor H‐based therapeutic concepts and modalities to treat complement‐mediated diseases.
Sebastiaan M. W. R. Hamers   +2 more
wiley   +1 more source

Multiple Myeloma as the Underlying Cause of Thrombotic Microangiopathy Leading to Acute Kidney Injury: Revisiting a Very Rare Entity

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2017
Thrombotic microangiopathy (TMA) describes a pathological process of microvascular thrombosis, consumptive thrombocytopenia, and microangiopathic hemolytic anemia, leading to end-organ ischemia and infarction, affecting particularly the kidney and brain.
Savneek Chugh MD   +4 more
doaj   +1 more source

Exercise‐induced vasculitis with histological and genetic evidence of complement involvement

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Massimo Cugno   +6 more
wiley   +1 more source

First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.
ABSTRACT This guideline summarizes diagnostic and therapeutic approaches based on a systematic literature review and evidence evaluation using the GRADE methodology. Given the limited high‐quality data, expert consensus was additionally obtained through a modified Delphi process.
Giorgia Olivieri   +26 more
wiley   +1 more source

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

open access: yesClinical Pharmacology: Advances and Applications, 2011
Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed ...
Ohanian M, Cable CC, Halka KK
doaj  

An Atypical Cause Of Atypical Hemolytic Uremic Syndrome

open access: yesMarshall Journal of Medicine, 2016
Atypical hemolytic syndrome is an extremely rare, life threatening, progressive disease. Approximately one to two cases per million are seen annually in the US (3,4).
Abhinav Sharma   +3 more
doaj   +1 more source

Vitamin‐Responsive Disorders: From Molecular Basis to Clinical Presentation and Therapy

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.
ABSTRACT Vitamin‐dependent cofactors are essential for numerous metabolic reactions, and defects affecting their uptake, conversion, utilisation, or regeneration constitute a heterogeneous group of inherited metabolic disorders (IMDs). Although dietary vitamin intake is sufficient to sustain coenzyme synthesis in healthy individuals, it is insufficient
Cécile Acquaviva   +5 more
wiley   +1 more source

Detection and Zoonotic Implications of Shiga Toxin–Producing Escherichia coli in Black Bengal Goats in Bangladesh

open access: yesVeterinary Medicine and Science, Volume 12, Issue 4, July 2026.
Low prevalence of STEC was detected in Black Bengal goats in Bangladesh; however, isolates carrying stx2, ehxA, saa, and subA highlight the presence of atypical strains with zoonotic potential. Identified risk factors emphasize the need for enhanced surveillance and improved farm hygiene practices to mitigate public health risks.
Shubho Sutradhar   +7 more
wiley   +1 more source

Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

open access: yesTransplant Infectious Disease, Volume 28, Issue 4, July/August 2026.
In this retrospective single‐center study of 220 kidney transplants from SARS‐CoV‐2 NAT+, NAT+ with COVID as cause of death (CoV‐COD) and NATneg donors, we found no significant difference in rejection or kidney pathologies at 1 year, and death, graft loss, or eGFR at 3 years by CoV‐donor status.
Christine E. Koval   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy